Aurora Cannabis Inc.

NASDAQ| TSX: ACB Re-affirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA 1 Following the receipt of EU-GMP certification in July, Safari Flower Company is expected to contribute incremental net revenue and adjusted EBITDA 1   Continued strong performance in Germany and Poland, contributing to profitable international growth expectations and leadership positions in the two largest EU markets, including #1 market share by revenue in Poland UK market expansion underway, with recently announced acquisition of Internode Pharma and HAP Pharma Limited expected to support further market share growth EDMONTON, AB, Sept. 16, 2026 /PRNewswire/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the leading Canadian-based global medical cannabis company, today provided a business update, highlighting the expected additional benefits of the Safari Flower Company acquisition, continued strong performance in key high margin international markets, and reaffirmed its fiscal year 2027 Q2 guidance.

Cross-border consolidation in the cannabis industry has moved from executive speculation into aggressive dealmaking. As regulatory hurdles begin to clear across North America and Europe, operators are moving quickly to strengthen their finances and expand globally.

Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The FactsPR NewswireEDMONTON, AB, Sept. 14, 2026NASDAQ | TSX: ACBCuraleaf's anno

NASDAQ | TSX: ACB Curaleaf's announcement is a desperate effort to shift attention away from the fundamental issue facing shareholders: its inadequate hostile bid undervalues Aurora. Curaleaf's attempt to fabricate issues ignores the reality of its own balance sheet: more than $1 billion of debt1, including $500 million carrying an 11.5% interest rate, exposing shareholders to significant financial and dilution risks.